Indefinite Delivery Contract SPE2DR25D3941

The Indefinite Delivery Contract (IDC) SPE2DR25D3941, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, is a $999,999,999 contract to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. This IDC serves as a primary vehicle for the DLA to efficiently procure essential pharmaceutical and medical supplies needed to serve the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined contracting mechanism. The IDC has a base period of 30 months and three 30-month option periods, supporting normal day-to-day operations as well as planned and unplanned contingencies, Prime Vendor Readiness, and War Readiness Materiel for both CONUS and OCONUS locations. The contract was awarded through an unrestricted and fully competitive acquisition process, with the intent to make multiple awards to ensure resiliency and access to vital pharmaceuticals.

The IDC is related to the upcoming DLA Troop Support Medical Supply Chain solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), which aims to establish Prime Vendor Contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, United States Coast Guard, and US Naval Fleet. The solicitation is expected to be issued in March 2024 and remain open for 45 days, with an estimated total value of $30.3 billion for the multiple awards across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet (CONUS/OCONUS) regions, as well as a Back-Up supplier. The awards will be made on a regional basis, with the intention to have at least three different contractors, to increase the Department of Defense's resiliency and access to vital pharmaceuticals during times of contingency or natural disasters.